drugset

drugset / Trial / NCT03006276

Efficacy, Tolerability, and Safety Study of DFN-15

NCT03006276 ↗

Phase 3 Completed 622 enrolled BioDelivery Sciences International

RandomizedParallel-groupTriple-blindTreatment

Summary

Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.

Timeline

Start: 2016-12
Primary completion: 2017-11
Completion: 2019-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DFN-15	Unknown	—	—

Indications